Logo image of CGON

CG ONCOLOGY INC (CGON) Stock Price, Quote, News and Overview

NASDAQ:CGON - Nasdaq - US1569441009 - Common Stock - Currency: USD

26.22  -0.34 (-1.28%)

After market: 26.22 0 (0%)

CGON Quote, Performance and Key Statistics

CG ONCOLOGY INC

NASDAQ:CGON (5/21/2025, 8:00:00 PM)

After market: 26.22 0 (0%)

26.22

-0.34 (-1.28%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High40.47
52 Week Low14.8
Market Cap2.00B
Shares76.22M
Float65.99M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO01-25 2024-01-25


CGON short term performance overview.The bars show the price performance of CGON in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 10 -10 20 -20

CGON long term performance overview.The bars show the price performance of CGON in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15

The current stock price of CGON is 26.22 USD. In the past month the price increased by 26.48%. In the past year, price decreased by -19.84%.

CG ONCOLOGY INC / CGON Daily stock chart

CGON Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 17.7 321.60B
AMGN AMGEN INC 13.07 145.89B
GILD GILEAD SCIENCES INC 13.92 134.11B
VRTX VERTEX PHARMACEUTICALS INC N/A 111.91B
REGN REGENERON PHARMACEUTICALS 13.65 65.28B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 38.06B
ARGX ARGENX SE - ADR 99.65 35.72B
ONC BEIGENE LTD-ADR 5.89 25.49B
BNTX BIONTECH SE-ADR N/A 23.82B
NTRA NATERA INC N/A 20.54B
SMMT SUMMIT THERAPEUTICS INC N/A 18.87B
BIIB BIOGEN INC 8.02 18.58B

About CGON

Company Profile

CGON logo image CG Oncology, Inc. is a clinical biopharmaceutical company, which engages in the development and commercialization of bladder-sparing therapeutic for patients afflicted with bladder cancer. The company is headquartered in Irvine, California and currently employs 113 full-time employees. The company went IPO on 2024-01-25. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Company Info

CG ONCOLOGY INC

400 Spectrum Center Drive, Suite 2040

Irvine CALIFORNIA US

Employees: 61

CGON Company Website

CGON Investor Relations

Phone: 19492886298

CG ONCOLOGY INC / CGON FAQ

What is the stock price of CG ONCOLOGY INC today?

The current stock price of CGON is 26.22 USD. The price decreased by -1.28% in the last trading session.


What is the ticker symbol for CG ONCOLOGY INC stock?

The exchange symbol of CG ONCOLOGY INC is CGON and it is listed on the Nasdaq exchange.


On which exchange is CGON stock listed?

CGON stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CG ONCOLOGY INC stock?

15 analysts have analysed CGON and the average price target is 63.88 USD. This implies a price increase of 143.62% is expected in the next year compared to the current price of 26.22. Check the CG ONCOLOGY INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CG ONCOLOGY INC worth?

CG ONCOLOGY INC (CGON) has a market capitalization of 2.00B USD. This makes CGON a Small Cap stock.


How many employees does CG ONCOLOGY INC have?

CG ONCOLOGY INC (CGON) currently has 61 employees.


What are the support and resistance levels for CG ONCOLOGY INC (CGON) stock?

CG ONCOLOGY INC (CGON) has a support level at 25.27 and a resistance level at 27.74. Check the full technical report for a detailed analysis of CGON support and resistance levels.


Is CG ONCOLOGY INC (CGON) expected to grow?

The Revenue of CG ONCOLOGY INC (CGON) is expected to decline by -10.89% in the next year. Check the estimates tab for more information on the CGON EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy CG ONCOLOGY INC (CGON) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CG ONCOLOGY INC (CGON) stock pay dividends?

CGON does not pay a dividend.


What is the Price/Earnings (PE) ratio of CG ONCOLOGY INC (CGON)?

CG ONCOLOGY INC (CGON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.51).


What is the Short Interest ratio of CG ONCOLOGY INC (CGON) stock?

The outstanding short interest for CG ONCOLOGY INC (CGON) is 17.01% of its float. Check the ownership tab for more information on the CGON short interest.


CGON Technical Analysis

ChartMill assigns a technical rating of 4 / 10 to CGON. When comparing the yearly performance of all stocks, CGON is a bad performer in the overall market: 74.22% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CGON Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to CGON. No worries on liquidiy or solvency for CGON as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CGON Financial Highlights

Over the last trailing twelve months CGON reported a non-GAAP Earnings per Share(EPS) of -1.51. The EPS decreased by -31.9% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -11.66%
ROE -12%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-25%
Sales Q2Q%-90.17%
EPS 1Y (TTM)-31.9%
Revenue 1Y (TTM)458.33%

CGON Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 81% to CGON. The Buy consensus is the average rating of analysts ratings from 15 analysts.

For the next year, analysts expect an EPS growth of -29.51% and a revenue growth -10.89% for CGON


Ownership
Inst Owners95.99%
Ins Owners1.54%
Short Float %17.01%
Short Ratio7.57
Analysts
Analysts81.33
Price Target63.88 (143.63%)
EPS Next Y-29.51%
Revenue Next Year-10.89%